By Using Mind.Px, Patients Achieve PASI75 Faster than Treatment-as-Usual Cohort

SAN DIEGO, CA – October 20, 2022 – Interim clinical utility and patient outcomes data regarding Mindera Health’s Mind.Px^™ test from the ongoing MATCH study were recently presented at the Fall Clinical Dermatology Conference 2022 in Las Vegas, one of the largest US-based dermatology educational meetings. These data validate the willingness of physicians to incorporate Mind.Px test results into their biologic decision making for psoriasis patients as well as demonstrate improved patient outcomes when the test reports were followed.

In the United States, psoriasis affects more than three percentⁱ of the population, leading to healthcare costs of more than $110 billion annually.ⁱⁱ Furthermore, successful patient responses to currently available biologic treatments are roughly 52 percentⁱⁱⁱ, leading to trial-and-error patient treatments and increased healthcare costs. Mind.Px is a predictive test used to improve management of psoriasis patients and allows physicians to prescribe biologic drugs with >92 percent positive predictive value.

The poster Trial-And-Error Prescribing Behavior Is Modified By A Psoriasis Precision Medicine Tool: Preliminary Clinical Utility Findings From The Match Study, led by Bruce E. Strober, MD, PhD, et al., was designed to evaluate the clinical utility of the Mind.Px diagnostic test in physician decision making and patient outcomes.

The interim results for this randomized study include 115 patients from 31 sites across the US over a 16-week treatment period, with roughly half of the patients randomized to the Mind.Px-informed arm versus a treatment-as-usual arm. Physicians were provided test results prior to biologic selection in the Mind.Px-informed arm. The study’s findings demonstrate:

• 88 percent of physician therapeutic choices that initiated dosing were aligned with Mind.Px test results; the primary reason to not follow the results were restrictions from insurance formularies;
• Only 55 percent of physician therapeutic choices were consistent with Mind.Px test results in the treatment-as-usual arm, supporting the previously published trial-and-error challenge for psoriasis patient management when prescribing biologic drugs; and
• An interim analysis of patients who have completed the MATCH study shows that by using Mind.Px results, patients reach clinical endpoints (PASI75) faster than those in the treatment-as-usual arm.

Mindera Health Chief Scientific Officer and Co-Founder Tobin J. Dickerson, PhD, stated, “These exciting interim data show that by using Mind.Px test results, patients reach clinical endpoints faster in a statistically significant manner. This is a key milestone in demonstrating the clinical utility of the test and, ultimately, incorporation into clinical practice.”

“Use of Mind.Px can effectively minimize the trial-and-error approach to psoriasis treatment and provide physicians, patients, and payers with a powerful tool for re-envisioning psoriasis patient care — the true vision of precision medicine,” commented George Mahaffey, President and CEO of Mindera Health.

About Mind.Px^™
Mind.Px is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample along with data analytics, Mind.Px materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments.

About Mindera Health^™
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.

---

ⁱMenter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057.

ⁱⁱPilon D, Teeple A, Zhdanava M, et al. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. J Med Econ. 2019;22(2):196-203. doi:10.1080/13696998.2018.1557201.

ⁱⁱⁱEnos CW, et al. Psoriasis severity, comorbidities, and treatment response differ among geographic regions in the United States. JID Innovations. 2021;1:100025.

Mind.Px provides clinically actionable information to physicians prior to treatment choice that significantly reduces “trial and error” biologic drug prescribing behavior, leading to improved psoriasis patient outcomes and reductions in wasted spending

 

SAN DIEGO, CA – July 26, 2022 – Mindera Health announces the publication, in the Journal of Drugs in Dermatology, of the recommendations from an expert consensus panel that supports adequate demonstration of clinical utility of the flagship Mind.Px precision medicine test if positive results from the MATCH Study are achieved.

Agreed-upon proof of clinical utility in a real-world setting is defined as the concordant use of test results by a physician in patient management decision-making that results in a positive health benefit for the patient. It is often required to eliminate barriers to coverage by payers, with the goal of ultimately improving patient care. This unique panel comprised dermatology key opinion leaders with expertise in psoriasis along with current and former chief medical officers from large payers or health systems. The panel reviewed clinical and economic study designs aimed at delineating net savings and wasted spending.

The MATCH Study is a 16-week randomized clinical utility evaluation of the pre-treatment impact of Mind.Px on biologic drug response rates in patients with psoriasis. The study is currently enrolling and approximately 100 of the targeted 200 patients are currently active. Interim analysis of physician concordance revealed a statistically significant change in physician prescribing behavior when provided Mind.Px test results. Indeed, these results show that physicians are 100% concordant with the results of Mind.Px if formulary restrictions are not taken into account. If physicians are required to comply with formulary restraints, the concordance rate is 93%. In the absence of access to Mind.Px precision medicine data, physicians prescribe biologics that are consistent with the test results 62.9% of the time.¹

Specialty drug spending is escalating at exponential rates, and biologics are often identified by payers, employers, and pharmacy benefit managers as being among their top drug expenditures each year.² Mind.Px addresses this directly with high physician utility (93%+) to optimize formulary performance. Mindera Health is in discussions with a variety of plans.

“We are extremely pleased to see that the expert panel consensus validates our MATCH Study design, accelerating our ability to engage with payers, brokers, and PBMs. By proactively addressing clinical utility, we now can continue very robust conversations with each of these stakeholders on how we can move forward with pilots or coverage decisions,” says George Mahaffey, President and CEO of Mindera Health.

About Mind.Px™

Mind.Px is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample and data analytics, Mind.Px materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments.

About Mindera Health™

Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, Next-Generation Sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA- and CAP-certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.

 

¹ “Trial-and-Error Prescribing Behavior is Modified by a Psoriasis Precision Medicine Tool: Preliminary Findings from the MATCH Study.” SCALE 2022, May 2022, Nashville, TN.
² “Prevalence and cost of autoimmune specialty drug use by indication in a 4.4 million member commercially insured population continuously enrolled four years, 2012 to 2015.” AMCP 2016, October 2016, National Harbor, MD; “Prevalence and cost of autoimmune specialty drug use by indication in a commercially insured population, January 2019 through June 2020.” AMCP 2021, April 2021, National Virtual Meeting.

Pilot designed to use clinical utility and patient outcomes to validate cost savings and address wasted spend and net savings from “trial and error” medicine

 

SAN DIEGO, CA – April 28, 2022 – Mindera Health™, the developer of the groundbreaking Dermal Intelligence™ platform – the first realization of precision medicine in psoriasis, has initiated a pilot program in California and Texas with a national health insurance company to assess the company’s groundbreaking Mind.Px™ test. The pilot program will evaluate trends in physician utilization, patient outcomes, drug switching and overall net savings versus a control group.

Mind.Px™ uses a painless dermal biomarker patch (DBP) to link each moderate to severe psoriasis patient with the most effective therapy for that unique patient, creating immense savings for the healthcare system and improving patient outcomes. The Mind.Px™ DBP and AI technology predict (91% PPV) the appropriate biologic drug class for an individual patient prior to treatment. By matching the patient to the right drug class before treatment begins, payers can potentially save up to $15,000 per patient in preventable “trial and error” medicine and could provide savings of millions of dollars for small groups up to hundreds of millions of dollars for large plans.

“Utilizing a pilot to validate our predicted costs saving while improving patient outcomes is the first of many steps in the accelerating national coverage of Mind.Px” says George Mahaffey, President, and CEO of Mindera Health.

Specialty drug spending is escalating at exponential rates, and biologics are often identified by payers, employers and pharmacy benefit managers as being in their top drug expenditures each year.[i] Mind.Px addresses this directly with high physician utility (90%+) to optimize formulary performance.

Ann Deren-Lewis, Chief Commercial Officer adds “Mind.Px is meant to reduce the trial-and-error process of prescribing biologics and help pharmacy benefit managers and insurance providers cut down on excessive spending while improving patient outcomes.”

 

About Mind.Px™

Mind.Px is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per samples and data analytics, Mind.Px materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments.

About Mindera Health™

Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, Next-Generation Sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.

###

 

[i] Source: Prime Therapeutics 2012-2015 and 2019-2020 posters entitled “Prevalence and Cost of Autoimmune Specialty Drug Use by Indication.”

Partnership to focus on improving patient outcomes while reducing healthcare system costs of expensive biologic therapeutics

SAN DIEGO, CA and LAKELAND, FL – January 4, 2022 – Mindera Health™ and WellDyne have entered into a definitive agreement to improve the management of psoriasis patients with moderate to severe disease using a proprietary dermal biomarker patch platform, Mind.Px™, that predicts the appropriate biologic drug class for an individual patient prior to treatment. Mindera Health is the developer of the groundbreaking Dermal Intelligence™ platform, the first realization of precision medicine in psoriasis. WellDyne is an innovative pharmacy benefit manager (PBM) with wholly-owned specialty and mail order pharmacies, a retail pharmacy network and clinical programs targeting complex conditions driving pharmacy trends today across the US. This synergistic collaboration capitalizes on the strengths of both companies and products to support improved treatment outcomes for psoriasis patients and reduce healthcare system costs of expensive biologics in the US.

Psoriasis affects nearly 3 percent of the US population, and of this group, many patients are diagnosed with moderate to severe disease which often requires treatment with expensive biologic therapeutics. The Mindera Health Mind.Px test uses a painless patch to determine an individual patient’s likelihood of response to all three major classes of biologic drugs approved for psoriasis. The patch provides physicians with a much-needed tool to predict response to expensive specialty drugs before treatment, which improves patient outcomes, reduces waste from drug cycling and creates net savings for payers.

WellDyne, which has partnered with more than 2,000 clients managing more than 3 million plan members, continuously develops easier, more accessible and lower-cost pharmacy solutions to help people live their healthiest and fullest lives.

“We are excited to partner with WellDyne and enable them to further optimize specialty drug spending for their clients by implementing Mind.Px, our groundbreaking precision medicine tool that predicts biologic drug response prior to treatment,” says George Mahaffey, President and CEO of Mindera Health. “We want to thank our strategic partner, Alva10, which specializes in connecting companies at the forefront of precision medicine with payers. Our partnership aligns the incentives of patient outcomes with payer economic utility and utilization.”

“Mind.Px delivers a best-in-class solution for optimizing specialty spend in psoriasis, and we are proud to offer it to our members,” says Nick Page, Chief Clinical Officer at WellDyne. “Our highly personalized approach to precision medicine embraces innovative, new tools that help create optimal outcomes for patients. We are developing industry-leading partnerships that leverage our deep clinical expertise for our clients in autoimmune categories and elsewhere.”

About Mind.Px™

Mind.Px is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per samples and data analytics, Mind.Px materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments.

About Mindera Health™

Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, Next-Generation Sequencing and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.

About WellDyne

For more than 25 years, WellDyne has leveraged its deep clinical expertise to achieve better outcomes and reduce pharmacy trend. Knowing that medications are the safest, easiest and lowest-cost treatments to help people live their best lives, the company believes a smarter approach to the delivery of PBM services unleashes the full power of medications to reduce future healthcare costs. Read more at www.welldyne.com.

 

 

Observational studies leverage machine learning to create Mind.Px^TM, a test that prospectively predicts biologic class response for individual psoriasis patients with high Positive Predictive Values (PPV)

SAN DIEGO, CA – November 16, 2021 – Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis,  has announced the publication of data and positive results from the observational STAMP-1 and STAMP-2 studies. These studies combined baseline dermal genetic testing using the Mind.Px™ platform to capture and analyze the whole transcriptome combined with proprietary artificial intelligence bioinformatics to develop predictive algorithms.

In 2019, the American Academy of Dermatology and the National Psoriasis Foundation published joint guidelines addressing care for the management and treatment of psoriasis with biologics. Amongst the many recommendations, the guidelines conclude with an important statement: “There is also an important need to identify biomarkers that can potentially predict the appropriate biologic agent for individual patients.”¹ The published data and results from the STAMP studies provide this information.

A total of 242 psoriasis patients were enrolled across these two studies, and biologic response predictive classifiers were developed and validated for each of the three biologic drug classes. Positive Predictive Values (PPV) for the classifiers (IL-23i, IL-17i and TNFai) were 93.1 percent, 92.3 percent and 85.7 percent, respectively, and balanced accuracy for all three was 69 percent.

Importantly, over the entire cohort, 99.5 percent of patients were predicted to respond to at least one drug class using a well-adopted clinical measure (PASI 75) at week 12, validating the broad efficacy of biologic drugs in the treatment of psoriasis.

“Applying machine learning to the transcriptomes collected during the STAMP studies has created a powerful predictive  tool that can provide guidance to dermatologists in choosing the right biologic for a psoriasis patient the first time,” said Tobin Dickerson, Chief Scientific Officer and Co-Founder of Mindera Health. “This study represents a critical milestone in bringing precision medicine to psoriasis patients.”

“The introduction of biologics to the treatment algorithm revolutionized psoriasis treatment, yet developing reliable data and tools for physicians to confidently prescribe the proper biologic therapy for an individual psoriasis patient to increase response rate is a significant unmet medical need,” said George Mahaffey, President and CEO of Mindera Health. “These positive results from the STAMP studies address this need to improve patient outcomes while significantly lowering healthcare system costs by reducing payer wasted spend and increasing net savings.”

About Mind.Px

Mind.Px is the flagship test of Mindera Health. The Mindera Health platform uses a dermal biomarker patch that takes only minutes to extract vast transcriptomic information. Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera Health scientists to take a genetic and transcriptomic snapshot of the skin. This rich patient-specific data set is then analyzed by machine learning algorithms to predict the appropriate biologic drug for an individual patient prior to therapeutic selection and treatment.

The ability to collect patient data at scale results in a powerful platform that unlocks cost savings for healthcare systems, particularly when applied to the prediction of response to hyper-expensive treatments. Biomarkers captured using the Mindera Health platform include DNA, RNA, protein, and small molecules.

About Mindera Health

Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level.  Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes.  Mindera Health is a CLIA and CAP certified Laboratory and has received ISO 13485:2016 certification.  Find out more at www.minderahealth.com.

Mind.Px brings personalized medicine to psoriasis patients by improving pre-treatment biologic drug class choice with >90% positive predictive value

SAN DIEGO – October 21, 2021 – Mindera Health, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis, announced the enrollment of the first patient in the MATCH Study. MATCH is a 16-week randomized clinical utility evaluation of the pre-treatment impact of Mind.Px on biologic drug response rates in patients suffering from psoriasis. The 200 patient study will include approximately 20 sites throughout the US.

According to a recent publication reporting data from the largest independent psoriasis registry (CorEvitas),[1] real-world patient response rates to hyper-expensive biologics were observed to be approximately 52%. These low response rates often lead to switching of therapies and massive wasted healthcare spending. With Mind.Px, physicians now have a predictive test to improve management of psoriasis patients and can prescribe biologic drugs with more confidence that a patient will achieve a desired outcome. Mind.Px produces a result with >90% positive predictive value (PPV), meaning that when Mind.Px predicts a patient will respond to a specific drug class, they do respond >90% of the time.

“Accessing and using an individual psoriasis patient’s baseline genetic biomarkers to prospectively predict that patient’s response to specific drugs and drug classes has been needed for many years”, says James Wang, MD, MBA, FAAD, Founder Metropolis Dermatology. “Being the dermatologist that enrolled the first patient into this important MATCH Study is exciting and we look forward to reporting the results in the near future.”

About Mind.Px

Mind.Px is the flagship test of Mindera Health. The Mindera Health platform uses a dermal biomarker patch that takes only minutes to extract vast transcriptomic information. Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera Health scientists to take a genetic and transcriptomic snapshot of the skin. This rich patient-specific data set is then analyzed by machine learning algorithms to predict the appropriate biologic drug for an individual patient prior to therapeutic selection and treatment.

The ability to collect patient molecular data at scale results in a powerful platform that unlocks cost savings for healthcare systems, particularly when applied to the prediction of response to hyper-expensive treatments. Biomarkers captured using the Mindera platform may include DNA, RNA, protein, and small molecules.

 About Mindera Health

Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level.  Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes.  Mindera is a CLIA and CAP certified Laboratory and has received ISO 13485:2016 certification.  Find out more at www.minderahealth.com.

---

¹ Enos CW, et al. Psoriasis Severity, Comorbidities, and Treatment Response Differ among Geographic Regions in the United States. JID Innovations 2021; 1:100025.

Combining Machine Learning with Next-Generation Sequencing creates Dermal Intelligence™: actionable information for payers, providers and patients to improve health outcomes and reduce healthcare spending.

(SAN DIEGO, CA – October 5, 2021) Mindera Corporation, developers of the groundbreaking Mind.Px™ – the first realization of truly personalized medicine in psoriasis – has changed its name to Mindera Health to better reflect the company’s data-driven precision medicine technology platform.

At the forefront of personalized medicine, the Mindera Health platform uses a patented, minimally invasive device to collect genetic biomarkers that correlate a patient’s transcriptome with that patient’s likely response to biologic treatments. By combining these genetic markers with machine learning, the Mindera Health platform helps physicians confidently choose what class of drug will work for an individual patient, the first time, eliminating wasted spending and improving patient outcomes.

The company’s first product, Mind.Px™, is focused on an uncharted territory in personalized medicine – dermatology – and the treatment of psoriasis, which afflicts 8 million individuals annually and represents a $25 billion market. Currently, nearly 48% of biologics failed in an average of 242 days, most often due to loss of efficacy,[1] and leading organizations including the American Academy of Dermatology have specifically called out the need to “identify biomarkers that can potentially predict the appropriate biologic agent for individual patients.”[2]

The company intends to use its patented technology platform using machine learning data-driven analytics for myriad indications and broad applications beyond dermatology in the future.

“Mindera Health is at the forefront of precision medicine, and our name change reflects our commitment to improving health and outcomes,” said George Mahaffey, CEO of Mindera Health. “This is a total paradigm shift for dermatology – we can deliver critical information to prospectively determine which biologic treatments could work best for individual patients using data collected from that patient – truly personalized medicine, here, today.”

About Mind.Px

Mind.Px is the flagship test of Mindera Health.  The platform uses a dermal biomarker patch that takes only minutes to extract vast transcriptomic information. Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera Health scientists to take a genetic and transcriptomic snapshot of the skin. This rich patient-specific data set is then analyzed by machine learning algorithms to predict the appropriate biologic drug for an individual patient prior to therapeutic selection and treatment. The ability to collect patient data at scale results in a powerful platform that unlocks cost savings for healthcare systems, particularly when applied to the prediction of response to hyper-expensive treatments. Biomarkers captured using the Mindera Health platform include DNA, RNA, protein, and small molecules.

About Mindera Health

Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level.  Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes.  Mindera Health is a CLIA and CAP certified Laboratory and has received ISO 13485:2016 certification.  Find out more at www.minderahealth.com.

---

¹ Levin AA, Gottlieb AB, Au SC. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. J Drugs Dermatol. 2014 Jul;13(7):848-53. PMID: 25007369.

² Joint AAD-NPR guidelines of care for the management and treatment of psoriasis with biologics.

Deren-Lewis will lead the company’s aggressive commercialization plans for the first personalized medicine platform specific to the dermatology industry.

(SAN DIEGO, CA – August 2, 2021) Mindera Corporation, developers of the groundbreaking Dermal Intelligence™ platform – the first realization of personalized medicine in dermatology – has appointed renowned industry veteran Ann Deren-Lewis as its Chief Commercial Officer.  Deren-Lewis brings over 30 years of leadership experience to the company with a proven track record in marketing, sales, product development, medical affairs and corporate development for Fortune 500 companies and start-ups.  She is a recognized leader in the dermatology industry and was one of the first non-dermatologists to become a member of the American Academy of Dermatology.

At Mindera, Deren-Lewis will lead the company’s commercial launch and growth plan for its Mind.Px, the organization’s flagship test to prospectively predict a patient’s response to expensive biologic drugs for psoriasis and other skin conditions.  Her primary initiatives will include building out the company’s systems and processes to maximize efficiencies, expanding the commercialization team to position Mind.Px for rapid adoption, and pioneering educational efforts with key opinion leaders in the dermatology industry.

“Ann has the demonstrated ability and distinct set of skills to support Mindera’s efforts to shape the era of digital predictive skin analytics and lead the market in Dermal Intelligence,” said George Mahaffey, CEO of Mindera. “Her experience in commercializing medical and aesthetic products and services, with an emphasis on psoriasis, is a perfect fit with our needs.”

“I have a passion for moving the needle on novel technologies,” commented Deren-Lewis. “The Mindera platform is one of the most innovative platforms I’ve seen and truly holds the potential to improve patient outcomes and decrease cost of care, and I am thrilled to be a part of the company.”

Deren-Lewis most recently served as Sr. Vice President of Corporate Development at Zerigo Health (formerly Clarify Medical) where she led commercial operations, including sales, marketing, medical affairs, and the clinical care team. Previously, Deren-Lewis was Founder and Principal of Two Blue Consulting working with a variety of clients in the medical and consumer goods industries.. She also holds boards seats with Afecta Phramaceuticals and Yorkshire Square Brewery.

Deren-Lewis holds a Master of Business Administration degree from Duke University and a Bachelor of Science degree from the University of North Carolina-Wilmington. 

About Mind.Px

Mind.Px is the flagship test of Mindera Corporation.  The Mindera platform uses a dermal biomarker patch that takes only minutes to extract vast transcriptomic information. Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera scientists to take a genetic and transcriptomic snapshot of the skin. This rich patient-specific data set is then analyzed by machine learning algorithms to predict the appropriate biologic drug for an individual patient prior to therapeutic selection and treatment. The ability to collect patient data at scale results in a powerful platform that unlocks cost savings for healthcare systems, particularly when applied to the prediction of response to hyper-expensive treatments. Biomarkers captured using the Mindera platform include DNA, RNA, protein, and small molecules.

About Mindera

Mindera is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level.  Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes.  Mindera is a CLIA and CAP certified Laboratory and has received ISO 13485:2016 certification.  Find out more at www.minderahealth.com.

Study shows 98% of dermatologists would utilize Mind.Px to predict biologic response for psoriasis patients

SAN DIEGO – July 26, 2021 – Mindera Corporation today announced that Dermatology and Therapy published results from a survey of 43 community-based dermatologists on behaviors and preferences of psoriasis-treating physicians.  The survey revealed a widespread and costly trial-and-error cycle in psoriasis biologic decision making, resulting in suboptimal patient outcomes and high wasted spending by payers.

Additionally, physicians expressed enthusiasm for Mind.Px™, a new precision medicine test that predicts individual patient response to psoriasis biologic classes with a high level of predictive value before a physician selects a biologic.  In contrast to the current trial-and-error prescribing behavior, the survey revealed that dermatologists view Mind.Px as a move towards dermatologic precision medicine.  Highlights of survey findings include:

• 82% of dermatologists report switching biologics for 10-30% of their patients within the first year of prescription
• 93% of dermatologists would utilize the Mind.Px test results over their own initial clinical choice
• 100% of dermatologists would use Mind.Px if it were integrated into the prior authorization process
• 98% of dermatologists say that Mind.Px would improve patient outcomes

The study was authored by key opinion leaders and authors of the Joint American Academy of Dermatology/National Psoriasis Foundation Guidelines of Care for the Management and Treatment of Psoriasis with Biologics, including Bruce Strober, MD PhD, David Pariser MD, Mark Lebwohl, MD, and Alan Menter, MD.  The guidelines, published in 2019, stated that there is “an important need to identify biomarkers that can potentially predict the appropriate biologic agent of individual patients.”

“Having the ability to proactively predict response to a biologic class with Mind.Px will enable physicians to finally have a tool to better prescribe the appropriate therapy the first time, significantly improving patient outcomes,” said Dr. Strober. “The potential benefits to the patient and the healthcare system are groundbreaking and the survey clearly shows the perceived clinical utility of this test.”

Mind.Px is the flagship test of Mindera Corporation.  The Mindera platform uses a dermal biomarker patch that takes only minutes to extract vast transcriptomic information. Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera scientists to take a genetic and transcriptomic snapshot of the skin. This rich patient-specific data set is then analyzed by machine learning algorithms to predict the appropriate biologic drug for an individual patient prior to therapeutic selection and treatment.

The ability to collect patient data at scale results in a powerful platform that unlocks cost savings for healthcare systems, particularly when applied to the prediction of response to hyper-expensive treatments. Biomarkers captured using the Mindera platform include DNA, RNA, protein, and small molecules.

About Mindera Health

Mindera is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level.  Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes.  Mindera is a CLIA and CAP certified Laboratory and has received ISO 13485:2016 certification.  Find out more at www.minderahealth.com.